Kairos Pharma, Ltd. Announces 1-for-7 Reverse Stock Split

What Happened Kairos Pharma, Ltd. (KAPA) filed an 8‑K reporting that its stockholders authorized the Board to implement a reverse stock split between 1-for-3 and 1-for-250. On August 18, 2026 the Board chose a 1-for-7 reverse stock split; the company filed a certificate of amendment on August 21, 2026 that becomes effective at the start of trading on September 1, 2026. The Company will trade on the NYSE American on a post‑split basis beginning at the Effective Time.

Key Details

• Reverse split ratio: 1-for-7 of issued and outstanding common stock.
• Important dates: stockholder approval June 29, 2026; Board authorization Aug. 18, 2026; certificate filed Aug. 21, 2026; effective/start of trading Sept. 1, 2026.
• Effect on securities: every 7 pre-split shares will convert into 1 post-split share; warrants and restricted stock units will be adjusted proportionally and warrant exercise prices will increase proportionally.
• Other facts: total authorized shares (common and preferred) unchanged; new CUSIP is 48301N203; VStock Transfer LLC is exchange agent; stockholders in street name need take no action.
• A press release announcing the reverse split was issued and is filed as an exhibit to the 8‑K.

Why It Matters The reverse stock split will reduce the number of shares outstanding and increase the per‑share figures (and per‑share exercise prices for warrants) on a 7:1 basis, and the company’s Common Stock will begin trading on a split‑adjusted basis on Sept. 1, 2026. The filing does not state a reason for the reverse split. Investors should note the new CUSIP and that equity awards and warrants will be adjusted proportionally; no action is required for shares held through brokers.